<DOC>
	<DOCNO>NCT00674102</DOCNO>
	<brief_summary>The safety , tolerability , efficacy pharmacokinetics ASA404 administer combination paclitaxel Carboplatin assess . ASA404 administer intravenously every 21 day Japanese patient Non small cell lung cancer .</brief_summary>
	<brief_title>An Open-label , Phase I Trial Intravenous ASA404 Administered Combination With Paclitaxel Carboplatin Japanese Patients With Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vadimezan</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion criterion : 1 . Histologically cytologically confirm nonsmall cell carcinoma lung . 2 . Newly diagnose Stage IIIb disease Stage IV disease 3 . No prior treatment Stage IIIb/IV nonsmall cell carcinoma lung ( Note : Prior neoadjuvant adjuvant chemotherapy within 6 month allow . ) 4 . Age ≥ 20 year old 5. WHO Performance status 01 6 . Lab value within range define within 2 week study registration ( Note : without use growth factor blood transfusion ) : Absolute neutrophil count ( ANC ) &gt; 2.0 x 109/L Platelets ≥ 100 x109/L Hemoglobin ≥ 9.5 g/dL Serum creatinine ≤ 1.5 x ULN 1.5 mg/dL Serum bilirubin ≤ 1.5 x ULN Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 2.5 x ULN PTINR ≤ 1.5 x ULN Potassium ≥ LLN correctable supplement . Total calcium ( correct serum albumin ) ≥ LLN correctable supplement . Magnesium ≥ LLN correctable supplement . Females childbearing potential must negative pregnancy test ( serum ) 7 . Life expectancy ≥ 12 week 8 . Written inform consent obtain accord local guideline Exclusion criterion : 1 . Patients symptomatic CNS metastases require treatment 2 . Patients second primary cancer , exception nonmelanoma skin cancer cervical cancer situ . 3 . Radiotherapy ≤ 4 week prior registration ( In case palliative radiotherapy 2 week prior registration 4 . Major surgery ≤ 4 week prior registration ( major surgery define use general anesthesia ) . Minor surgery ≤ 2 week prior registration . Insertion vascular access device allow . Patients must recover surgeryrelated complication . 5 . Concurrent use investigational agent patient receive investigational agent ≤ 4 week prior registration 6 . Prior exposure VDAs vascular target agent ( antiVEGF , antiVEGF receptor agent , antiEGFR agent 7 . Patients pleural effusion drain ( Patients recurrence pleural effusion and/or take 2 week registration drainage allow ) 8 . Patients recent hemoptysis associate NSCLC ( &gt; 1 teaspoon single episode within 4 week ) 9 . Known allergy hypersensitivity platinumcontaining drug , taxanes , drug formulate Cremophor EL ( polyoxyethylated castor oil ) known excipients drug . 10 . Peripheral sensory neuropathy functional impairment ( CTC Grade 2 neuropathy , regardless causality ) 11 . ≥ CTC Grade 2 cardiac arrhythmia ( i.e . symptomatic , may require medication ) . 12 . Pregnant breast feeding females 13 . Patients take medicine know prolong QT interval 14 . Women child bear potential sexually active male , unwilling unable use require highly effective method ( ) contraception sex receive treatment least 6 month discontinuation study treatment . ( Adequate form contraception include IUD , oral depot contraceptive barrier method plus spermicide . ) 15 . Patients one follow Patients Long QT Syndrome Patients Baseline 12lead ECG QTc &gt; 450 msec male &gt; 470 msec female . Congestive heart failure ( NY Heart Association class III IV ) Patients myocardial infarction within 12 month study entry Unstable poorly control angina pectoris History poorly control hypertension antihypertensive regimen History sustain ventricular tachycardia Any history ventricular fibrillation Torsades de Pointes Right bundle branch block leave anterior hemiblock ( bifasicular block ) Bradycardia define heart rate &lt; 50 beat per minute 16 . Concurrent severe and/or uncontrolled medical disease ( i.e . uncontrolled diabetes , chronic renal disease , chronic liver disease , confirm diagnosis HIV infection active uncontrolled infection ) . 17 . Patients know HBV HCV positive 18 . Significant neurological psychiatric disorder could compromise participation study 19 . Patient unwilling unable comply protocol 20 . Patients adequate enter study decide investigator medical point view . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Vascular disrupting agent</keyword>
	<keyword>Non-small cell lung cancer</keyword>
</DOC>